Stay updated with breaking news from Per Protocol. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
A statistically significant, 37.4% difference , slowing of disease progression in ALSFRS-R, in patients treated with PrimeC compared to placebo, in the pre-specified Per Protocol population...
A statistically significant, 37.4% difference (P=0.03), slowing of disease progression in ALSFRS-R, in patients treated with PrimeC compared to placebo, in the...
Acurx Pharmaceuticals Inc (NASDAQ: ACXP) shares are trading lower after the company
NaturalVue® Multifocal 1 Day Contact Lenses Confirmed Safe & Effective for Myopia Management ...
INSIDE INFORMATION Prior efficacy unmatched but excellent safety profile confirmed, timing of ALLOB administration for optimal bone repair to...